CLSI vs. EUCAST breakpoints

Ref ID: 19470

Author:

S. R. Lockhart

Author address:

Centers for Disease Control and Prevention, Lilburn, USA

Full conference title:

6th Trends in Medical Mycology 2013

Date: 11 October 2014

Abstract:

The European Committee on Antimicrobial Susceptibility Testing (EU-
CAST) and the Clinical and Laboratory Standards Institute (CLSI) are
international organizations which establish susceptibility breakpoints for various antimicrobial/pathogen combinations. Both organizations
have a subcommittee addressing susceptibility testing of yeasts and
molds. Because the standardized methodologies for yeast and mold
susceptibility testing established by the two organizations are not
identical, there are differences in their final published breakpoints.
There are two other major differences between the two groups. The
first is that EUCAST has established Candida breakpoints for the anti-
fungal agents posaconazole and Amphotericin B based on pharmaco-
kinetic data, epidemiological cutoff values and clinical experience;
CLSI has no such breakpoints. The second is that EUCAST has estab-
lished breakpoints for Amphotericin B, itraconazole, voriconazole and
posaconazole against Aspergillus species while the CLSI has not estab-
lished any mold-specific breakpoints. This talk will discuss the differ-
ences in the breakpoints established by the two organizations, the
differences in the antifungal and yeast/mold combinations for which
breakpoints have been established, and perspectives the two groups
can take from each other in terms of the best methodologies for
establishing meaningful antifungal breakpoints going forward.

Abstract Number: W17.4

Conference Year: 2013

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster